Russell Investments Group Ltd. Has $7.86 Million Holdings in Insulet Co. (NASDAQ:PODD)

Russell Investments Group Ltd. trimmed its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 16.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,168 shares of the medical instruments supplier's stock after selling 7,088 shares during the period. Russell Investments Group Ltd. owned about 0.05% of Insulet worth $7,863,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PODD. Baillie Gifford & Co. acquired a new stake in shares of Insulet during the fourth quarter worth $263,144,000. William Blair Investment Management LLC boosted its holdings in shares of Insulet by 145.1% during the third quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier's stock worth $116,894,000 after purchasing an additional 433,884 shares during the last quarter. Northern Trust Corp raised its position in shares of Insulet by 7.6% in the 3rd quarter. Northern Trust Corp now owns 681,731 shares of the medical instruments supplier's stock worth $108,729,000 after buying an additional 47,938 shares during the period. Westfield Capital Management Co. LP raised its position in shares of Insulet by 62.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 637,261 shares of the medical instruments supplier's stock worth $101,637,000 after buying an additional 244,922 shares during the period. Finally, Qube Research & Technologies Ltd raised its position in shares of Insulet by 227.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier's stock worth $61,673,000 after buying an additional 268,553 shares during the period.

Insider Activity at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.47% of the stock is currently owned by insiders.

Insulet Stock Performance

Shares of Insulet stock traded down $8.71 during trading on Wednesday, hitting $175.57. 1,071,767 shares of the stock were exchanged, compared to its average volume of 850,820. The stock's fifty day moving average is $170.32 and its 200 day moving average is $181.66. The stock has a market cap of $12.29 billion, a PE ratio of 60.33, a P/E/G ratio of 3.14 and a beta of 1.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $331.65.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping the consensus estimate of $0.67 by $0.73. The business had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company's quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.55 earnings per share. As a group, sell-side analysts anticipate that Insulet Co. will post 3.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on PODD shares. JPMorgan Chase & Co. increased their target price on Insulet from $190.00 to $225.00 and gave the stock an "overweight" rating in a research report on Friday, February 23rd. Stifel Nicolaus increased their target price on Insulet from $163.00 to $208.00 and gave the stock a "hold" rating in a research report on Monday, February 5th. Barclays cut their target price on Insulet from $214.00 to $213.00 and set an "equal weight" rating on the stock in a research report on Monday, February 26th. Piper Sandler cut their price objective on Insulet from $250.00 to $230.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. Finally, Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $200.00 price objective on the stock in a research report on Tuesday. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of "Moderate Buy" and an average price target of $240.33.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.